Becton Dickinson and Co (NYSE:BDX) had its Outperform rating reiterated by Wells Fargo & Co with a $290.00 price target

ME Staff
-
0

Analyst Ratings For Becton Dickinson and Co (NYSE:BDX)

Today, Wells Fargo & Co reiterated its Outperform rating on Becton Dickinson and Co (NYSE:BDX) with a price target of $290.00.

There are 10 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Becton Dickinson and Co (NYSE:BDX) is Buy with a consensus target price of $251.0769 per share, a potential 1.71% downside.

Some recent analyst ratings include

  • 9/6/2018-Becton Dickinson and Co (NYSE:BDX) had its Outperform rating reiterated by Wells Fargo & Co with a $290.00 price target
  • 8/3/2018-Becton Dickinson and Co (NYSE:BDX) had its Hold rating reiterated by Royal Bank of Canada with a $248.00 price target
  • 8/3/2018-Becton Dickinson and Co (NYSE:BDX) had its Buy rating reiterated by KeyCorp with a $264.00 price target
  • 6/21/2018-Becton Dickinson and Co (NYSE:BDX) gets upgraded to Overweight by JPMorgan Chase & Co. with a price target of $175.00
  • 3/5/2018-Becton Dickinson and Co (NYSE:BDX) has coverage initiated with a Market Perform rating and $249.00 price target

Recent Insider Trading Activity For Becton Dickinson and Co (NYSE:BDX)
Becton Dickinson and Co (NYSE:BDX) has insider ownership of 1.00% and institutional ownership of 86.73%.

  • On 5/21/2018 Alexandre Conroy, Insider, sold 20,128 with an average share price of $228.74 per share and the total transaction amounting to $4,604,078.72.
  • On 5/11/2018 Nabil Shabshab, EVP, sold 10,209 with an average share price of $226.10 per share and the total transaction amounting to $2,308,254.90.
  • On 5/7/2018 David F Melcher, Director, bought 500 with an average share price of $225.07 per share and the total transaction amounting to $112,535.00.
  • On 3/13/2018 Thomas E Polen Jr, EVP, sold 1,877 with an average share price of $227.00 per share and the total transaction amounting to $426,079.00.
  • On 2/27/2018 John E Gallagher, VP, sold 5,346 with an average share price of $226.08 per share and the total transaction amounting to $1,208,623.68.
  • On 2/26/2018 James W Borzi, EVP, sold 4,048 with an average share price of $224.98 per share and the total transaction amounting to $910,719.04.
  • On 2/23/2018 Timothy M Ring, Director, sold 176 with an average share price of $218.27 per share and the total transaction amounting to $38,415.52.

About Becton Dickinson and Co (NYSE:BDX)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Recent Trading Activity for Becton Dickinson and Co (NYSE:BDX)
Shares of Becton Dickinson and Co closed the previous trading session at 255.75 −1.95 0.76% with 257.89 shares trading hands.